+1.224.938.9523

HUMAN AMYLOID IMAGING CONFERENCE

The 15th edition of the HAI will be held in Miami, FL on January 11-13, 2023.

2023 PROGRAM

The event will be held at the James L. Knight Center located downtown Miami, FL at 400 SE 2nd Ave. 

WEDNESDAY, JANUARY 11
7:30 AM
Check-in and Breakfast
8:15 AM
Welcome Notes; Introductions
8:25 AM
Announcement: Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET): Defining the future of Alzheimer's treatment, imaging and care
8:30 AM
SESSION I: TRACER DEVELOPMENT AND EVALUATION
8:30 AM
Introduction
8:35 AM
Advances towards the identification of an α-synuclein Positron Emission Tomography radioligand for the diagnosis of Parkinson’s disease
8:50 AM
Discovery of [18F]ACI-12589, a novel and promising PET-tracer for a-synuclein
9:05 AM
Discovery and preclinical evaluation of two novel PET tracers for imaging non-AD tauopathies
9:20 AM
In vivo head-to-head comparison of [18F]GTP1, [18F]PI2620, and [18F]MK6240 in Alzheimer’s disease
9:35 AM
DIDACTIC PRESENTATION: ANTIBODY PET
10:00 AM
Session I Discussion
10:30 AM
P1 - POSTER SESSION/BREAK
11:15 AM
SESSION II: TECHNICAL ADVANCES FOR CLINICAL APPLICATIONS
11:15 AM
Introduction
11:20 AM
Minimizing sample sizes for trials using MK-6240 outcomes: impact of processing method and choice of reference and target tissues
11:35 AM
Inferring full ATN status from tau-PET using deep learning
11:50 AM
Longitudinal modelling of tau transport and production dynamics in the human brain
12:05 PM
Connectivity- versus gradient-based approaches to predict regional tau-PET across Alzheimer’s disease variants
12:20 PM
Measuring tau in the basal forebrain: a comparison of MK6240 and flortaucipir
12:35 PM
Session II Discussion
1:00 PM
LUNCH
2:00 PM
KEYNOTE: SYNAPTIC PATHOLOGY IN NEURODEGENERATION
2:30 PM
Keynote Discussion
2:45 PM
SESSION III: THRESHOLDS, VISUAL READS AND REAL WORLD IMAGING
2:45 PM
Introduction
2:50 PM
Biostatistical estimation of tau threshold hallmarks (BETTH) for tau imaging studies
3:05 PM
Visual read of [18F]florquinitau PET that includes and extends beyond the mesial temporal lobe is associated with amyloid positivity and retrospective cognitive decline in an AD risk-enriched cohort
3:20 PM
Head-to-head comparison of tau and amyloid PET visual reads for differential diagnosis: An international, multi-center study
3:35 PM
Quantitative analysis of 8,895 real-world amyloid Positron Emission Tomography (PET) scans from the Imaging Dementia–Evidence for Amyloid Scanning (IDEAS) study
3:50 PM
Session III Discussion
4:15 PM
P2: POSTER SESSION/BREAK
5:00 PM
SESSION IV: NON-AD AND CO-PATHOLOGIES
5:00 PM
Introduction
5:05 PM
Tau burden evaluation by [18F] Flortaucipir PET and quantitative tau neuropathology in Alzheimer's disease and non-Alzheimer’s tauopathies
5:20 PM
Pathologic correlations of [18F]-Flortaucipir imaging in non-Alzheimer corticobasal syndrome
5:35 PM
Unveiling the neurobiological basis of F18-flortaucipir in different tauopathies using voxel-to-voxel histology to PET comparisons: the role of p-tau, iron and MAOB
5:50 PM
Association of FDG-PET with co-pathologies in autopsy-proven AD
6:05 PM
Session IV Discussion
6:30 PM
RECEPTION
9:00 PM
DAY 1 ENDS
WEDNESDAY, JANUARY 11
7:30 AM
Check-in and Breakfast
8:15 AM
Keith Johnson, MD, Massachusetts General Hospital
8:25 AM
Maria Carrillo, PhD, Alzheimer's Association
8:30 AM
CHAIRS: Julie Price, PhD, Massachusetts General Hospital
Chet Mathis, PhD, University of Pittsburgh
8:30 AM
Chairs
8:35 AM
Idriss Bennacef, PhD, Merck & Co.
8:50 AM
Francesca Capotosti, PhD, AC Immune
9:05 AM
Marc Skaddan, PhD, AbbVie
9:20 AM
Matteo Tonietto, PhD, F. Hoffman-La Roche
9:35 AM
Dag Sehlin, PhD, Uppsala University
10:00 AM
Session I Discussion
10:30 AM
P1 - POSTER SESSION/BREAK
11:15 AM
CHAIRS: Suzanne Baker, PhD, Lawrence Berkeley National Laboratory
Bradley Christian, PhD, University of Wisconsin, Madison
11:15 AM
Chairs
11:20 AM
J. Alex Becker, PhD, Massachusetts General Hospital
11:35 AM
Nicolai Franzmeier, PhD, LMU Munich
11:50 AM
Pavan Chaggar, PhD, University of Oxford
12:05 PM
Nick Corriveau-Lecavalier, PhD, Mayo Clinic, Rochester
12:20 PM
Theresa Harrison, PhD, University of California, Berkeley
12:35 PM
Session II Discussion
1:00 PM
LUNCH
2:00 PM
Thomas Montine, MD, Stanford University
2:30 PM
Keynote Discussion
2:45 PM
CHAIRS: Pedro Rosa-Neto, MD, PhD, McGill University
Ansel Hillmer, PhD, Yale School of Medicine
2:45 PM
Chairs
2:50 PM
Alexandra Gogola, PhD, University of Pittsburgh School of Medicine
3:05 PM
Sterling Johnson, PhD, University of Wisconsin School of Medicine and Public Health
3:20 PM
David Soleimani-Meigooni, PhD, University of California, San Francisco
3:35 PM
Ehud Zeltzer, MD, University of California, San Francisco
3:50 PM
Session III Discussion
4:15 PM
P2: POSTER SESSION/BREAK
5:00 PM
CHAIRS: Milos Ikonomovic, MD, University of Pittsburgh
Melissa Murray, PhD, Mayo Clinic, Jacksonville
5:00 PM
Chairs
5:05 PM
Rodolfo Gatto, PhD, Mayo Clinic, Rochester
5:20 PM
Cinthya Aguero, MD, MassGeneral Institute for Neurodegenerative Disease
5:35 PM
Yuheng Chen, PhD, University of California, San Francisco
5:50 PM
Marianne Chapleau, PhD, University of California, San Francisco
6:05 PM
Session IV Discussion
6:30 PM
RECEPTION
9:00 PM
DAY 1 ENDS
THURSDAY, JANUARY 12
7:30 AM
Breakfast
8:30 AM
SESSION V: AD NEUROPATHOLOGY
8:30 AM
Introduction
8:35 AM
Specific associations between plasma biomarkers and post-mortem amyloid plaque and neurofibrillary tau tangle loads
8:50 AM
Intersection of amyloid-β and tau brain pathology influences plasma phosphorylated tau levels
9:05 AM
Tangle maturity markers associate with tau PET and cognitive measures in hippocampus
9:20 AM
Postmortem validation of 18F-MK-6240 PET using autoradiography and in-vitro binding combined with antibody-based assays in frozen brains from two autopsy cases
9:35 AM
Session V Discussion
10:00 AM
P3: POSTER SESSION/BREAK
10:45 AM
SESSION VI: HETEROGENEITY IN THE AD CASCADE
10:45 AM
Introduction
10:50 AM
Longitudinal increases in tau emerge alongside early amyloid change in Down syndrome
11:05 AM
Cross-sectional and longitudinal associations between amyloid- and tau-PET in early-onset Alzheimer’s Disease: update from the LEADS study
11:20 AM
Amyloid PET Burden Predicts Longitudinal Cognitive Trajectories in a Heterogeneous ADRD Cohort
11:35 AM
Variations in gamma-secretase function across PSEN1 pathogenic variants strongly predict the clinical, cognitive, and biomarker progression of autosomal dominant Alzheimer’s disease (MGH, DIAN)
11:50 AM
Session VI Discussion
12:15 PM
LUNCH
1:15 PM
SESSION VII: TAU PET AND MRI: MULTIMODALITY INSIGHTS
1:15 PM
Introduction
1:20 PM
Mapping tau accumulation to the functional and structural organization of the brain in Alzheimer’s disease
1:35 PM
Baseline tau PET shows stronger associations with cognitive and behavioral changes over time than cortical thickness
1:50 PM
A Central Role of Locus Coeruleus in the Initial Spatiotemporal Progression of Tau and its Contribution to Cognition
2:05 PM
Tau Propagation in the Brain Olfactory Circuits Contributes to Smell Perception Changes in Aging
2:20 PM
Medial temporal lobe subregional microstructure measured with ultra-high resolution diffusion imaging as a biomarker for early tau pathology and memory impairment (UCI)
2:35 PM
Session VII Discussion
3:00 PM
KEYNOTE: On making neuroimaging studies more equitable, inclusive, and relevant
3:30 PM
Keynote Discussion
3:45 PM
P4: POSTER SESSION/BREAK
4:30 PM
SESSION VIII: LIFESTYLE AND LIVED EXPERIENCES
4:30 PM
Introduction
4:35 PM
African American racialization modifies the association between apolipoprotein-E4 and amyloid deposition
4:50 PM
Cardiovascular risk and AD biomarkers in unimpaired older adults: A comparison of U.S. POINTER and ADNI
5:05 PM
Association between mid-life social factors and estimated late life amyloid burden: the Atherosclerosis Risk in Communities (ARIC)-PET study
5:20 PM
Session VIII Discussion
5:45 PM
RECEPTION
8:00 PM
DAY 2 ENDS
THURSDAY, JANUARY 12
7:30 AM
Breakfast
8:30 AM
CHAIRS: Teresa Gomez-Isla, MD, PhD, Massachusetts General Hospital
Laetitia Lemoine, PhD, Karolinska Institutet
8:30 AM
Chairs
8:35 AM
Gemma Salvado, PhD, Lund University
8:50 AM
Melissa Murray, PhD, Mayo Clinic, Jacksonville
9:05 AM
Christina Moloney, PhD, Mayo Clinic, Jacksonville
9:20 AM
Tobey Betthauser, PhD, University of Wisconsin-Madison
9:35 AM
Session V Discussion
10:00 AM
P3: POSTER SESSION/BREAK
10:45 AM
CHAIRS: Heidi Jacobs, PhD, Massachusetts General Hospital
Susan Landau, PhD, University of California, Berkeley
10:45 AM
Chairs
10:50 AM
Matt Zammit, PhD, University of Wisconsin-Madison
11:05 AM
Nidhi Mundada, PhD, University of California, San Francisco
11:20 AM
Kyan Younes, PhD, Stanford University
11:35 AM
Stephanie Schultz, PhD, Massachusetts General Hospital
11:50 AM
Session VI Discussion
12:15 PM
LUNCH
1:15 PM
CHAIRS: Annie Cohen, PhD, University of Pittsburgh
Beth Mormino, PhD, Stanford University
1:15 PM
Chairs
1:20 PM
Julie Ottoy, PhD, University of Toronto
1:35 PM
Ellen Singleton, PhD, Lund University
1:50 PM
Elisenda Bueicheku, PhD, Massachusetts General Hospital/Harvard Medical School
2:05 PM
Ibai Diez, PhD, Massachusetts General Hospital/Harvard Medical School
2:20 PM
Jenna Adams, PhD, University of California, Irvine
2:35 PM
Session VII Discussion
3:00 PM
Monica Rivera Mindt, PhD, Fordham University
3:30 PM
Keynote Discussion
3:45 PM
P4: POSTER SESSION/BREAK
4:30 PM
CHAIRS: Gil Rabinovici, MD, University of California, San Francisco
Tobey Betthauser, PhD, University of Wisconsin-Madison
4:30 PM
Chairs
4:35 PM
Sarah Royse, PhD, University of Pittsburgh
4:50 PM
Susan Landau, PhD, University of California, Berkeley
5:05 PM
Renee Groechel, PhD, NINDS
5:20 PM
Session VIII Discussion
5:45 PM
RECEPTION
8:00 PM
DAY 2 ENDS
FRIDAY, JANUARY 13
7:30 AM
Breakfast
7:45 AM
NEW!Mentor Session
9:00 AM
SESSION IX: LONGITUDINAL CHANGES IN TAU AND AMYLOID MARKERS
9:00 AM
Introduction
9:05 AM
Longitudinal tau accumulation is associated with faster memory decline in typical aging and preclinical Alzheimer’s disease
9:20 AM
The use of plasma markers to predict tau accumulation in a stage-specific manner
9:35 AM
Temporal dynamics of plasma pTau217 and amyloid PET in preclinical AD
9:50 AM
Longitudinal changes in Alzheimer’s disease-related plasma biomarkers in relation to changes in PiB PET measures of brain amyloid
10:05 AM
Longitudinal bidirectional associations between sleep and Alzheimer’s pathology in at-risk cognitively unimpaired older adults
10:20 AM
Session IX Discussion
10:45 AM
P5: POSTER SESSION/BREAK
11:30 AM
SESSION X: FLUID BIOMARKERS IN AD
11:30 AM
Introduction
11:35 AM
Plasma p-tau217 ratios associated with amyloid and tau PET measures in preclinical AD: Findings from the AHEAD 3-45 Study screening data
11:50 AM
Plasma biomarkers as stand-alone tests to rule out Alzheimer's disease
12:05 PM
Comparative performance of three plasma Aβ42/Aβ40 and two plasma p-tau181 assays versus amyloid-PET imaging status
12:20 PM
Prognostic utility of plasma p217+tau vs amyloid and tau PET in the Alzheimer continuum
12:35 PM
Associations of blood biomarkers with early-onset Alzheimer’s disease pathology
12:50 PM
Associations between amyloid PET, CSF pTau, and plasma biomarkers in memory clinic patients
1:05 PM
LUNCH
2:05 PM
Session X Discussion
2:30 PM
KEYNOTE: BIOFLUIDS AND IMAGING: TWO SIDES OF THE SAME COIN
3:00 PM
Keynote Discussion
3:15 PM
P6: POSTER SESSION/BREAK
4:00 PM
AWARDS
4:15 PM
SESSION XI: PLASMA WITH OTHER MODALITIES
4:15 PM
Introduction
4:20 PM
Plasma biomarkers associated with cortical brain structure and multi-domain cognition in Alzheimer’s disease and Parkinson’s disease
4:35 PM
Relationships of blood insulin with brain structures and plasma Aβ42 to Aβ40 ratio in a multi-ethnic cohort of older adults
4:50 PM
Unique biological pathways associated with plasma ptau species and AD PET: an imaging-transcriptomic study
5:05 PM
Session XI Discussion
5:30 PM
CONCLUDING REMARKS
5:35 PM
CONFERENCE ENDS
FRIDAY, JANUARY 13
7:30 AM
Breakfast
7:45 AM
NEW!Mentor Session
9:00 AM
CHAIRS: Keith Johnson, MD Massachusetts General Hospital
William Jagust, MD, University of California, Berkeley
9:00 AM
Chairs
9:05 AM
Corrina Fonseca, PhD, University of California, Berkeley
9:20 AM
Cécile Tissot, PhD, McGill University
9:35 AM
Karly Cody, PhD, University of Wisconsin-Madison
9:50 AM
Murat Bilgel, PhD, NIA
10:05 AM
Bery Mohammediyan, MSc, McGill University
10:20 AM
Session IX Discussion
10:45 AM
P5: POSTER SESSION/BREAK
11:30 AM
CHAIRS: Henrik Zetterberg, MD, PhD, University of Gothenburg
Donna Wilcox, PhD, University of Kentucky College of Medicine
11:30 AM
Chairs
11:35 AM
Reisa Sperling, MD, MGH/Harvard Medical School
11:50 AM
Joseph Therriault, PhD, McGill University
12:05 PM
Alicia Algeciras-Schimnich, PhD, Mayo Clinic, Rochester
12:20 PM
Azadeh Feizpour, PhD, Austin Health
12:35 PM
Paige Logan, PhD, Indiana University School of Medicine
12:50 PM
Marina Bluma, PhD, Karolinska University
1:05 PM
LUNCH
2:05 PM
Session X Discussion
2:30 PM
Thomas Karikari, PhD, University of Pittsburgh School of Medicine
3:00 PM
Keynote Discussion
3:15 PM
P6: POSTER SESSION/BREAK
4:00 PM
AWARDS
4:15 PM
CHAIR: Thomas Karikari, PhD, University of Pittsburgh
Suzanne Schindler, MD, PhD, Washington University
4:15 PM
Chairs
4:20 PM
Gillian Coughlan, PhD, Massachusetts General Hospital
4:35 PM
Brandon Hall, MSc, University of Southern California
4:50 PM
Min Su Kang, PhD, Sunnybrook Research Institute
5:05 PM
Session XI Discussion
5:30 PM
Teresa Gomez-Isla, MD, PhD, Massachusetts General Hospital
Thomas Karikari, PhD, University of Pittsburgh
Beth Mormino, PhD, Stanford University
Julie Price, PhD, Massachusetts General Hospital
5:35 PM
CONFERENCE ENDS